JP2011505356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505356A5 JP2011505356A5 JP2010535919A JP2010535919A JP2011505356A5 JP 2011505356 A5 JP2011505356 A5 JP 2011505356A5 JP 2010535919 A JP2010535919 A JP 2010535919A JP 2010535919 A JP2010535919 A JP 2010535919A JP 2011505356 A5 JP2011505356 A5 JP 2011505356A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99126507P | 2007-11-30 | 2007-11-30 | |
| PCT/SE2008/051370 WO2009070116A1 (en) | 2007-11-30 | 2008-11-28 | A quinoline derivative acting as a p2x7-receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505356A JP2011505356A (ja) | 2011-02-24 |
| JP2011505356A5 true JP2011505356A5 (enExample) | 2012-02-02 |
Family
ID=40676391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535919A Withdrawn JP2011505356A (ja) | 2007-11-30 | 2008-11-28 | Ｐ２ｘ７受容体アンタゴニストとして作用するキノリン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8106073B2 (enExample) |
| EP (1) | EP2225222B1 (enExample) |
| JP (1) | JP2011505356A (enExample) |
| AR (1) | AR069508A1 (enExample) |
| AT (1) | ATE524458T1 (enExample) |
| ES (1) | ES2370960T3 (enExample) |
| PE (1) | PE20091036A1 (enExample) |
| TW (1) | TW200932229A (enExample) |
| WO (1) | WO2009070116A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2460727C2 (ru) * | 2007-03-22 | 2012-09-10 | Астразенека Аб | Хинолиновые производные для лечения воспалительных заболеваний |
| PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
| AU2010340142B2 (en) * | 2009-12-17 | 2014-05-08 | Merck Sharp & Dohme Corp. | Quinoline amide M1 receptor positive allosteric modulators |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| MX2014000894A (es) | 2011-07-22 | 2014-02-27 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7. |
| TWI576347B (zh) | 2012-01-20 | 2017-04-01 | 艾克泰聯製藥有限公司 | 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物 |
| KR102232742B1 (ko) | 2012-12-12 | 2021-03-26 | 이도르시아 파마슈티컬스 리미티드 | Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체 |
| WO2014097140A1 (en) | 2012-12-18 | 2014-06-26 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| JP6282016B2 (ja) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| JP6282017B2 (ja) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| JP6692759B2 (ja) * | 2014-06-05 | 2020-05-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規キノリン誘導体及び神経変性疾患におけるそれらの使用 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3352912A (en) | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3471491A (en) | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| GB1274652A (en) | 1968-08-27 | 1972-05-17 | Lilly Industries Ltd | Adamantanyl-alkylamine derivatives and their preparation |
| IL53441A0 (en) | 1977-11-22 | 1978-01-31 | Teva Pharma | Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them |
| US4751292A (en) | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| DK0501656T3 (da) | 1991-02-21 | 1997-07-21 | Sankyo Co | Benzenderivater med en fremskyndende aktivitet på produktion af nervevækstfaktor |
| PL181782B1 (pl) | 1993-08-10 | 2001-09-28 | Black James Foundation | Nowe zwiazki i sposób wytwarzania nowych zwiazków PL |
| DE69531458T2 (de) | 1994-05-27 | 2004-08-05 | Glaxosmithkline S.P.A. | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
| AR004735A1 (es) | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
| NZ332341A (en) | 1996-05-20 | 2000-05-26 | Darwin Discovery Ltd | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors |
| FR2761358B1 (fr) | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU771358B2 (en) | 1997-11-21 | 2004-03-18 | Astrazeneca Ab | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| TR200102911T2 (tr) | 1999-04-09 | 2002-01-21 | Astrazeneca Ab | Adamantan türevleri. |
| CH1196397H1 (de) | 1999-06-02 | 2007-05-31 | Nps Pharma Inc | Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems. |
| WO2001037826A1 (en) | 1999-11-26 | 2001-05-31 | Shionogi & Co., Ltd. | Npyy5 antagonists |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| CA2452606C (en) | 2001-07-02 | 2011-09-13 | Akzo Nobel N.V. | Tetrahydroquinoline derivatives |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| AU2003226149A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| WO2008013494A1 (en) | 2006-07-27 | 2008-01-31 | Astrazeneca Ab | Quinoline derivatives as p2x7 receptor antagonist and their use in the treatment of rheumatoid arthritis, osteoarthritis, copd and ibd |
| RU2460727C2 (ru) * | 2007-03-22 | 2012-09-10 | Астразенека Аб | Хинолиновые производные для лечения воспалительных заболеваний |
| PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
-
2008
- 2008-11-26 PE PE2008001976A patent/PE20091036A1/es not_active Application Discontinuation
- 2008-11-26 US US12/324,397 patent/US8106073B2/en not_active Expired - Fee Related
- 2008-11-28 TW TW097146304A patent/TW200932229A/zh unknown
- 2008-11-28 AT AT08855156T patent/ATE524458T1/de not_active IP Right Cessation
- 2008-11-28 WO PCT/SE2008/051370 patent/WO2009070116A1/en not_active Ceased
- 2008-11-28 AR ARP080105220A patent/AR069508A1/es unknown
- 2008-11-28 EP EP08855156A patent/EP2225222B1/en not_active Not-in-force
- 2008-11-28 JP JP2010535919A patent/JP2011505356A/ja not_active Withdrawn
- 2008-11-28 ES ES08855156T patent/ES2370960T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006182786A5 (enExample) | ||
| JP2009542613A5 (enExample) | ||
| JP2009537498A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2011518202A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| JP2008195730A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| JP2009543860A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| WO2008000483A3 (en) | Phenol derivatives for the treatment of respiratory diseases | |
| JP2015502974A5 (enExample) | ||
| TWI455938B (zh) | 碳酸啶衍生物及其醫藥組成物 | |
| JP2012513390A5 (enExample) | ||
| JP2010505865A5 (enExample) | ||
| JP2019529460A5 (enExample) | ||
| MXPA05013856A (es) | Agonistas del receptor sht2c para el tratamiento de diabetes y obesidad. | |
| JP2012144537A5 (enExample) |